本文選題：腦心通膠囊 + 心肌梗塞��； 參考：《中華中醫(yī)藥學(xué)刊》2017年06期

【摘要】：目的:探討步長(zhǎng)腦心通膠囊對(duì)門(mén)診就醫(yī)的心肌梗塞患者血清脂聯(lián)素(APN)、氨基末端腦鈉肽前體(NT-proBNP)水平及心功能的影響。方法:選取2013年3月—2016年2月醫(yī)院收治的87例心肌梗塞患者為研究對(duì)象,按數(shù)字表法將所有患者隨機(jī)分為對(duì)照組(n=43)和觀察組(n=44),兩組患者均給予常規(guī)西藥治療,觀察組患者加服腦心通膠囊1.6 g/次,3次/d,連續(xù)治療4周;超聲檢查肱動(dòng)脈內(nèi)徑,心電圖檢查評(píng)估梗死面積及心電圖QRS評(píng)分,采用電化學(xué)發(fā)光全自動(dòng)免疫分析儀檢測(cè)NT-proBNP水平,ELISA法測(cè)定APN水平,放射免疫法測(cè)定ET水平,硝酸鹽還原酶法測(cè)定NO,比較兩組患者治療前后心功能指標(biāo)、梗死面積、心電圖QRS評(píng)分及血清ET、NO、APN、NT-proBNP水平變化。結(jié)果:治療后兩組患者心功能指標(biāo)均有明顯改善LVDd、LVST顯著降低,LVEF顯著升高(P0.05),治療后觀察組LVEF明顯高于對(duì)照組(P0.05);與治療前比較,兩組治療后心肌梗死面積及心電圖QRS評(píng)分、血清ET、NT-proBNP水平均顯著降低(P0.05),FMD、NMD及血清NO、APN水平均顯著升高(P0.05),治療后觀察組心肌梗死面積及心電圖QRS評(píng)分、FMD、NMD、NO、ET、APN、NT-proBNP與對(duì)照組比較有統(tǒng)計(jì)學(xué)差異(P0.05)。結(jié)論:步長(zhǎng)腦心通膠囊可改善心肌梗塞患者心功能,降低心肌梗死面積,可能與上調(diào)脂聯(lián)素及下調(diào)NT-proBNP水平,改善血管內(nèi)皮功能有關(guān)。
[Abstract]:Objective: to investigate the effects of Buchang Naoxintong capsule on serum adiponectin (APN), amino-terminal brain natriuretic peptide precursor (NT-proBNP) and cardiac function in out-patient patients with myocardial infarction. Methods: 87 patients with myocardial infarction admitted in our hospital from March 2013 to February 2016 were randomly divided into two groups: control group (n = 43) and observation group (n = 44). The patients in both groups were treated with routine western medicine. The patients in the observation group were treated with Naoxintong capsule 1.6 g / time for 3 times / d for 4 weeks, and the internal diameter of brachial artery was examined by ultrasound, and the infarct area and QRS score of ECG were evaluated by electrocardiogram. The levels of NT-proBNP were measured by Elisa, et by radioimmunoassay and no by nitrate reductase. The indexes of cardiac function and infarct area were compared before and after treatment. The QRS score of ECG and the level of NT-proBNP in serum ETG NON were changed. Results: the cardiac function indexes of the two groups were significantly improved after treatment (P0.05), the LVEF in the observation group was significantly higher than that in the control group (P0.05), the myocardial infarction area and the QRS score of electrocardiogram (QRS) in the two groups after treatment were significantly higher than those in the control group (P0.05), and LVEF in the observation group was significantly higher than that in the control group (P0.05). Serum ETNT-proBNP levels were significantly decreased (P0.05) and serum NON-APN levels were significantly increased (P0.05). After treatment, the size of myocardial infarction and the QRS score of ECG QRS in the observation group were significantly higher than those in the control group (P0.05). Conclusion: Buchang Naoxintong capsule can improve cardiac function and reduce myocardial infarction size in patients with myocardial infarction, which may be related to the up-regulation of adiponectin and the down-regulation of NT-proBNP level and the improvement of vascular endothelial function.
【作者單位】： 航空總醫(yī)院;北京市昌平區(qū)中西結(jié)合醫(yī)院;
【基金】：北京市中醫(yī)藥管理局青年基金項(xiàng)目(QN2008-23)
【分類號(hào)】：R542.22

【相似文獻(xiàn)】

相關(guān)期刊論文 前7條

1 李淑珍;肖波;;步長(zhǎng)腦心通膠囊、抗凝劑合用治療心絞痛40例臨床分析[J];中國(guó)實(shí)用醫(yī)藥;2008年02期

2 劉榮啟;;應(yīng)用步長(zhǎng)腦心通膠囊治療糖尿病合并心腦血管病的療效分析[J];當(dāng)代醫(yī)藥論叢;2014年10期

3 葉世華;魏振華;黃潔蓮;楊繼俊;陳怡;梁宇;劉志偉;王瓊兒;單文;劉建;;步長(zhǎng)腦心通膠囊對(duì)冠心病合并高血脂患者的臨床療效[J];當(dāng)代醫(yī)學(xué);2012年16期

4 郭宏;胡雪梅;;應(yīng)用步長(zhǎng)腦心通膠囊治療心腦血管疾病的療效觀察[J];亞太傳統(tǒng)醫(yī)藥;2012年06期

5 衛(wèi)海松;高海旺;王亮亮;王翠平;牛振山;王俏梅;李小芬;謝澤彥;;步長(zhǎng)腦心通膠囊治療冠狀動(dòng)脈慢血流的臨床研究[J];慢性病學(xué)雜志;2010年09期

6 劉玉東;;步長(zhǎng)腦心通膠囊與阿司匹林聯(lián)合應(yīng)用在心腦血管疾病一二級(jí)預(yù)防分析[J];醫(yī)藥與保健;2014年01期

7 ;[J];;年期

，

本文編號(hào)：2064532